Key facts
- Bryn Pharma’s last known valuation is $225.0M (Oct 2022).
- It has raised $127.4M across 4 recorded rounds; the latest was Early Stage VC ($26.7M) in Apr 2023.
- Bryn Pharma has filed 8 Form Ds with the SEC since 2019, most recently Jul 2023 ($26.7M sold to 105 investors).
- Status: Out of Business.
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for Bryn Pharma
Funding rounds
4 roundsAbout Bryn Pharma
Operator of a biotechnology company intended to offer nasal-based epinephrine for anaphylaxis. The company specializes in creating a bi-dose intranasal device that is an alternative to epinephrine auto-injectors and is needle-free, easy to use without any special medical training, portable, affordable, and small enough to comfortably carry in a pocket, enabling patients to treat allergic reactions or anaphylaxis reactions.
- Sector
- Healthcare
- HQ
- Raleigh, NC, United States
- Founded
- 2016
- Employees
- 10
- Website
- brynpharma.com/
- Ownership
- Out of Business
Bryn Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bryn Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bryn Pharma in its N-PORT filings yet. We sweep new filings monthly.